Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 639,541 shares of the company's stock after selling 8,808 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 1.38% of Omnicell worth $28,421,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of OMCL. Smartleaf Asset Management LLC lifted its stake in shares of Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after buying an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new position in shares of Omnicell in the fourth quarter valued at about $37,000. Van ECK Associates Corp lifted its holdings in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the period. Headlands Technologies LLC acquired a new position in Omnicell in the 4th quarter worth approximately $53,000. Finally, First Horizon Advisors Inc. raised its position in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after buying an additional 355 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on OMCL shares. Benchmark cut their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Wells Fargo & Company upgraded Omnicell from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $31.00 to $35.00 in a research report on Wednesday, May 14th. Finally, StockNews.com lowered Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday, May 3rd. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $46.50.

Omnicell Price Performance

Omnicell stock traded up $0.36 during trading on Tuesday, reaching $28.21. The company had a trading volume of 132,411 shares, compared to its average volume of 557,219. The firm has a market capitalization of $1.32 billion, a PE ratio of 104.47, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The firm's 50-day simple moving average is $31.30 and its 200 day simple moving average is $39.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $0.03 earnings per share. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.